(Q43262220)

17 November 2017

title

Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy (English)

1 reference

17 November 2017

1 reference

5

Björn Dahlöf

0 references

Kurt Boman

object named as

Kurt Boman

1

1 reference

ORCID Public Data File 2021

author name string

Jenny Hernestål Boman

2

1 reference

17 November 2017

Jonas Andersson

3

1 reference

17 November 2017

Mona Olofsson

4

1 reference

17 November 2017

language of work or name

1 reference

13 October 2009

1 reference

Clinical and Applied Thrombosis-Hemostasis

17 November 2017

published in

1 reference

17 November 2017

volume

16

1 reference

17 November 2017

issue

2

1 reference

17 November 2017

page(s)

146-152

1 reference

Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1076029609349501

Biosynthesis of von Willebrand protein by human megakaryocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609349501

Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609349501

Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609349501

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609349501

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609349501

Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1076029609349501

21 January 2018

Identifiers

DOI

10.1177/1076029609349501

1 reference

17 November 2017

1 reference